 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| albumin-interferon alpha2b fusion protein / FortuneRock (China)
Trial completion, Phase classification, Enrollment change, Trial completion date: Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient (clinicaltrials.gov) - Apr 1, 2021
P1/2, N=11, Completed, Sponsor: Tianjin SinoBiotech Ltd.
Recruiting --> Completed | Phase classification: P1 --> P1/2 | N=32 --> 11 | Trial completion date: Oct 2019 --> Mar 2021
- | albumin-interferon alpha2b fusion protein / FortuneRock (China)
Trial completion date: Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient (clinicaltrials.gov) - Sep 13, 2019
P1, N=32, Recruiting, Sponsor: Tianjin SinoBiotech Ltd.
Recruiting --> Completed | Phase classification: P1 --> P1/2 | N=32 --> 11 | Trial completion date: Oct 2019 --> Mar 2021 Trial completion date: May 2019 --> Oct 2019
- | albumin-interferon alpha2b fusion protein / FortuneRock (China)
New P1 trial: Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient (clinicaltrials.gov) - Sep 27, 2017
P1, N=32, Recruiting, Sponsor: Tianjin SinoBiotech Ltd.
- | albumin-interferon alpha2b fusion protein / FortuneRock (China)
Trial completion, Trial primary completion date: Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Chinese Healthy Volunteers (clinicaltrials.gov) - May 8, 2017
P1, N=34, Completed, Sponsor: Tianjin SinoBiotech Ltd.
Trial completion date: May 2019 --> Oct 2019 Recruiting --> Completed | Trial primary completion date: Feb 2017 --> Aug 2016
- | albumin-interferon alpha2b fusion protein / FortuneRock (China)
New P1 trial: Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Chinese Healthy Volunteers (clinicaltrials.gov) - May 24, 2016
P1, N=34, Recruiting, Sponsor: Tianjin SinoBiotech Ltd.